AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 1 - (NewsRx.com & NewsRx.net) -- Confluent Surgical, Inc., announced the commencement of its pivotal U.S. trial for the SprayGel Adhesion Barrier in Prevention of Pelvic Adhesions In Laparoscopic Surgery, the PREVAIL Study. Confluent Surgical believes that the SprayGel Adhesion Barrier will prevent and reduce adhesions that are associated with severe postoperative pain and other side effects, which affect millions of women annually.
The first procedure in the PREVAIL Study was performed by Michael L. Twede, MD, FACOG, and Dale A. Sundwall, MD, FACOG, Medical Directors at the Salt Lake City Women's Center. Twede and Sundwall are considered experts in the treatment of endometriosis and adhesions and are respected as highly skilled surgeons.
Twede states, "Based on the early published results, SprayGel appears to represent a breakthrough in adhesion prevention. It is unique in its ability to be applied laparoscopically and remain in place as a barrier for five to seven days, the period when adhesions normally form. If the results from the initial pilot study are replicated in this pivotal study, this product would prevent or significantly reduce patient trauma and costs ...